- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Blood cancer study yields disappointing results
19 July 2016 • Author: Niamh Louise Marriott
Swiss drugmaker Roche today announced that the Phase III GOYA study of Gazyvaro (obinutuzumab, also known in the US as Gazyva) did not meet its primary endpoint of significantly reducing the risk of disease worsening or death in people with previously untreated diffuse large B-cell lymphoma compared to Rituxan (rituximab), an alternative, when combined with CHOP chemotherapy.
Unfortunately, adverse effects with both Gazyvaro and Rituxan were consistent with those seen in previous clinical trials when each was combined with various chemotherapies. These effects, and all other data, will be presented at an upcoming medical meeting.
“Two previous studies showed Gazyvaro helped people with previously untreated follicular lymphoma or chronic lymphocytic leukaemia live longer without their disease worsening compared to Rituxan. We were hopeful to show a similar result for people with diffuse large B-cell lymphoma and once again improve on the standard of care”, said Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development.
“We will continue to analyse the GOYA data to better understand the results, and to study other investigational treatments in this disease with the goal of further helping these patients”.
Gazyvaro is currently approved in more than 70 countries in combination with chlorambucil for people with previously untreated chronic lymphocytic leukaemia.
Successful clinical trials would not only help fend off cheaper competition for biosimilar copies of both Rituxan and Gazyvaro, which are to be available on the market within the next couple of years, but also help a much wider range of cancer patients with successful treatments.
Diffuse large B-cell lymphoma is the most common form of non-Hodgkin’s lymphoma with an estimated 25,000 new US cases of the aggressive blood cancer, and 10,000 deaths from it seen each year.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics